A Step Closer to ADC as a Biomarker in Clinical Practice.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Objective value of the apparent diffusion coefficient (ADC) map from ultrahigh b-value diffusion-weighted imaging (DWI) in 3T MRI as a non-invasive predictor for Gleason score in prostate cancer.Quantitative imaging in medicine and surgery · 2026
   Article
2. Diagnostic value of whole-tumor ADC histogram parameters combined with ISUP grade and MRI-EPE score for predicting extracapsular extension in PI-RADS 4-5 prostate cancer.Frontiers in oncology · 2026
   Article

Corrections and comments

• Comment on
  The QIBA Profile for Diffusion-Weighted MRI: Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker.2024

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as